Trials / Recruiting
RecruitingNCT07114861
The KN510713 Study in Combination With mFOLFIRINOX
An Open-label, Dose-finding and Dose-expansion, Phase I/IIa Clinical Trial to Evaluate the Safety and Efficacy of KN510713 in Combination With mFOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- New Cancer Cure-Bio Co.,Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety and efficacy of KN510713 in combination with mFOLFIRINOX in patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in two parts: Part 1 (Dose-finding) and Part 2 (Dose expansion).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX | KN510 120mg/day + KN713 90mg/day: once daily in 14-day (2-week) cycles. mFOLFIRINOX: Treatment is repeated every 2 weeks |
| DRUG | Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX | KN510 120mg/day + KN713 120mg/day: once daily in 14-day (2-week) cycles. mFOLFIRINOX: Treatment is repeated every 2 weeks |
Timeline
- Start date
- 2025-12-16
- Primary completion
- 2028-09-22
- Completion
- 2028-10-22
- First posted
- 2025-08-11
- Last updated
- 2026-04-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07114861. Inclusion in this directory is not an endorsement.